Prolung Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Prolung Inc (FRES) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Prolung Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Prolung Inc | - | - | - | Yes |
| Competitors combined (12) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
FRES Stock Performance relative to its Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Bioaffinity Technologies Inc | 282.9% | Outperformed |
| 2 | Ovid Therapeutics Inc | 282.9% | Outperformed |
| 3 | Livanova Plc | 282.9% | Outperformed |
| 4 | Si bone inc | 282.9% | Outperformed |
| 5 | Orthopediatrics Corp | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Prolung Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Prolung Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Prolung Inc | 3.90 | - |
| Astrazeneca Plc | 252,216.14 | 58,739.00 |
| Stryker Corp | 106,300.54 | 25,837.00 |
| Gsk Plc | 99,157.95 | 43,093.89 |
| Resmed Inc | 32,292.54 | 5,628.17 |
| Livanova Plc | 4,304.66 | 1,470.11 |
| SUBTOTAL | 497,836.35 | 136,638.07 |
Sign in to see all competitors of Prolung Inc .
Sources: Prolung Inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Prolung Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Prolung Inc's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Bioaffinity Technologies Inc | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Prolung Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Prolung Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Stryker Corp | MedSurg and Neurotechnology 55.02 % |
| Resmed Inc | Sleep and Breathing Health 88.58 % |
| Livanova Plc | Cardiopulmonary 57.68 % |
| Ovid Therapeutics Inc | Reportable 100.00 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Prolung Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Prolung Inc | 4 | - | - |
| Astrazeneca Plc | 252,216 | 706,847 | 123,141 |
| Stryker Corp | 106,301 | 461,375 | 66,589 |
| Gsk Plc | 99,158 | 169,660,977 | 32,662,867 |
| Resmed Inc | 32,293 | 495,002 | 133,975 |
| Livanova Plc | 4,305 | 445,488 | 57,137 |
| PEERS TOTAL | 497,832 | 861,706 | 150,069 |
Prolung Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Stryker Corp | United States 75.26 % |
| Resmed Inc | Combined Europe Asia and other markets 31.05 % |
| Livanova Plc | United States 51.05 % |
| Nuvasive Inc | United States 75.71 % |
| Si bone inc | United States 95.04 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Prolung Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2015 | 2016 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Revenue Growth | - | - | - | - | - | - |
| Operating Margin | - | - | - | - | - | - |
| Return on Invested Capital | 168.55 % | 106.40 % | 54.65 % | 21.63 % | 11.87 % | 17.97 % |
| P/E | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Prolung Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Return on equity 22.4 points above the industry aggregate.
Weaknesses
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
No rule matched.
Threats
No rule matched.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Prolung Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Prolung Inc | 0.07 | 0.07 | - |
| Astrazeneca Plc | 0.19 | 0.94 | 0.51 |
| Stryker Corp | 0.48 | 1.99 | 0.68 |
| Gsk Plc | 0.16 | 0.82 | 0.87 |
| Resmed Inc | 1.14 | 3.09 | 0.11 |
| Livanova Plc | 0.75 | 1.36 | 0.28 |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Prolung Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Prolung Inc | Q4 2022 | - | - |
| Astrazeneca Plc | Q4 2025 | +8.6 % | +45.3 % |
| Stryker Corp | Q2 2026 | +9.4 % | +44.3 % |
| Gsk Plc | Q4 2025 | +7.5 % | +120.0 % |
| Resmed Inc | Q2 2026 | +9.2 % | +1.0 % |
| Livanova Plc | Q2 2026 | +10.8 % | +299.7 % |
| PEERS TOTAL | +8.2 % | +68.0 % |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Prolung Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Prolung Inc | Q4 2022 | - | - |
| Astrazeneca Plc | Q4 2025 | +11.2 % | +46.0 % |
| Stryker Corp | Q2 2026 | -4.1 % | +10.4 % |
| Gsk Plc | Q4 2025 | +7.2 % | -0.6 % |
| Resmed Inc | Q2 2026 | +15.9 % | +69.6 % |
| Livanova Plc | Q2 2026 | +3.0 % | +108.3 % |
Prolung Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Prolung Inc | - | - | - |
| Astrazeneca Plc | 8.97% | 19.67% | 21.00% |
| Stryker Corp | 7.89% | 8.80% | 16.36% |
| Gsk Plc | 10.09% | 44.94% | 38.67% |
| Resmed Inc | 17.80% | 20.01% | 24.21% |
| Livanova Plc | 7.31% | 10.40% | 15.41% |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Prolung Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Prolung Inc | - | - |
| Astrazeneca Plc | 24.67 | 4.29 |
| Stryker Corp | 28.54 | 4.11 |
| Gsk Plc | 17.35 | 2.30 |
| Resmed Inc | 21.22 | 5.74 |
| Livanova Plc | 22.57 | 2.93 |
| PEERS AVERAGE | 20.92 | 3.64 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.